Companies › AP Biosciences
4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AP402 HER2-targeting immunoconjugate | ERBB2 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| AP203 | – | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Dec 2026 |
| AP601 Bispecific antibody targeting CD73 | CD73 | Phase 1 | Solid Tumours | Dec 2027 |
| AP505 Anti-PD-L1 and Anti-VEGF antibody fusion protein | CD274, VEGFA | Phase 1 | Advanced Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06723964 | AP505 | Phase 1 | Advanced Solid Tumors | Oncology | Oct 2024 |
| NCT06669975 | AP402 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT05473156 | AP203 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Dec 2026 |
| NCT07165067 | AP601 | Phase 1 | Solid Tumours | Oncology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.